Ipilimumab Combination Dosing: Less is More.

ABSTRACT: Ipilimumab with and without anti-Programmed Death 1 (PD-1) improved overall survival (OS) in melanoma. Despite this, the optimal dose and therapeutic mechanism of ipilimumab in patients remains unclear. KEYNOTE-029 and other studies suggest that low-dose ipilimumab with anti-PD1 maintains efficacy while decreasing toxicity, emphasizing T-cell trafficking and reinvigoration as likely mechanisms. See related article by Long et al., p. 5280.

SUBMITTER: Jameson-Lee M 

PROVIDER: S-EPMC8807780 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature